PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC is investigating Passage Bio’s proposed merger with Remix Therapeutics. Passage Bio shareholders are expected to own approximately 7% of the combined company upon closing; the notice provides no further details about the investigation or transaction terms.

Analysis

The 7% ownership figure is a negotiating and governance signal, not by itself evidence that Passage Bio shareholders are receiving poor value: the relevant comparison is the value contributed by each company, including cash, liabilities, pipeline assets, and expected funding needs. Those inputs, along with the exchange mechanics and any contingent consideration, are absent here, so neither dilution nor deal value can be assessed from the ownership split alone.

The immediate risk is headline-driven volatility around a law-firm investigation. Such announcements are not findings of misconduct; absent a substantive challenge, the investigation itself is unlikely to alter the economics. Over the next 1–3 months, the decision-useful catalysts are definitive merger terms, proxy disclosure, independent fairness analysis, shareholder support, and any court or regulatory developments. A challenge becomes more material if it identifies specific disclosure gaps or seeks to delay closing. Conversely, clear disclosure and shareholder approval would reduce process risk, not establish that the combined company is fairly valued.

There is no grounded directional trade from this item alone. Any event-driven position would require the deal terms, current PASG price, closing conditions, and expected timing to estimate the spread and downside if the transaction breaks. The contrarian point is that investors may overread both the 7% headline and the word “investigating”: the former is not a standalone valuation metric, and the latter is not evidence of a deal defect.

Key Decisions for Investors

• Do not trade PASG solely on the investigation notice; treat it as a low-information legal headline unless a specific challenge or requested remedy emerges.
• Set an event watch for the merger proxy and definitive terms: verify implied value to PASG holders, fully diluted ownership, cash and liabilities contributed, contingent payments, termination provisions, and closing conditions.
• Reassess deal-break risk if a court filing identifies material omissions, closing is delayed, or shareholder support weakens; a clear proxy and completed vote would reduce process uncertainty.
• Keep any merger-arbitrage idea on hold until the consideration, PASG market price, closing timeline, and break value are available; those missing inputs determine whether the spread compensates for execution risk.